Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.41 |
| ▸ | CTSG | P08311 | 2/20 | 0.41 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.41 |
| ▸ | CMA1 | P23946 | 2/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11560111 | 0.79 | NPSR1 (0.43) | NPSR1L3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8561805 | 0.79 | NPSR1 (0.48) | POLBNPSR1L3MBTL1NPC1RAB9A | |
| SCHEMBL8071295 | 0.77 | RIPK1 (0.45) | NPSR1L3MBTL1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL4516395 | 0.76 | POLB (0.71) | POLBNPSR1L3MBTL1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL10589406 | 0.76 | RIPK1 (0.44) | NPSR1L3MBTL1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL9614618 | 0.75 | RAB9A (0.45) | POLBNPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL8561812 | 0.75 | POLB (0.47) | POLBNPSR1L3MBTL1NPC1RAB9A | |
| SCHEMBL5514730 | 0.75 | POLB (0.42) | POLBNPSR1L3MBTL1NPC1RAB9A | |
| SCHEMBL13994618 | 0.74 | POLB (0.58) | POLBNPSR1L3MBTL1NPC1RAB9A | |
| SCHEMBL28456818 | 0.73 | POLB (0.57) | POLBNPC1RAB9ASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0294035-B1 | Benzoylaminophenoxybutanoic acid derivatives | ONO PHARMACEUTICAL CO (JP) | 1994-08-31 | — | — | EP | claimed |
| EP-0576603-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO. INC. (US) | 1994-01-05 | — | — | EP | claimed |
| WO-1992018132-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA COMTAINING A 5 ALPHA-REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 1992-10-29 | — | — | WO | claimed |
| WO-1992016213-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | claimed |
| WO-1992016233-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC CANCER CONTAINING A 5 ALPHA REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | claimed |
| EP-0291245-B1 | BENZOYLAMINOPHENOXYBUTANOIC ACID DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 1992-07-22 | — | — | EP | claimed |
| US-4980372-A | INHIBITORS OF 5-ALPHA-REDUCTASE; TREATING AND PREVENTING ALOPECIA, ACNES OR PROSTATIC HYPERTROPHY | ONO PHARMACEUTICAL CO., LTD. (JP) | 1990-12-25 | — | — | US | claimed |
| US-4935240-A | Benzoylaminophenoxybutanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1990-06-19 | — | — | US | claimed |
| EP-0294035-A2 | Benzoylaminophenoxybutanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1988-12-07 | — | — | EP | claimed |
| EP-0291245-A2 | Benzoylaminophenoxybutanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1988-11-17 | — | — | EP | claimed |
| JP-1156950-A | — | — | None | — | — | JP | disclosed |
| US-20250127749-A1 | METHOD FOR TREATING METASTATIC PROSTATE CANCER | THE WILLIAM M YARBROUGH FOUND (US) | 2025-04-24 | — | — | US | disclosed |
| US-12178795-B2 | Method for treating metastatic prostate cancer | THE WILLIAM YARBROUGH FOUNDATION (US) | 2024-12-31 | — | — | US | disclosed |
| US-11633376-B2 | Method for treating metastatic prostate cancer | THE WILLIAM M. YARBROUGH FOUNDATION (US) | 2023-04-25 | — | — | US | disclosed |
| US-20210228528-A1 | METHOD FOR TREATING METASTATIC PROSTATE CANCER | THE WILLIAM M. YARBROUGH FOUNDATION | 2021-07-29 | — | — | US | disclosed |
| EP-0294035-A2 | Benzoylaminophenoxybutanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1988-12-07 | — | — | EP | disclosed |
| EP-0294035-A2 | Benzoylaminophenoxybutanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1988-12-07 | — | — | EP | disclosed |
| EP-0291245-A2 | Benzoylaminophenoxybutanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1988-11-17 | — | — | EP | disclosed |
| EP-0291245-A2 | Benzoylaminophenoxybutanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1988-11-17 | — | — | EP | disclosed |
| EP-0291245-A2 | Benzoylaminophenoxybutanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1988-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12178795-B2 | Method for treating metastatic prostate cancer | BPHL, KLK3, ACP3 | POLB 1583/4885NPSR1 1562/4885L3MBTL1 2958/4885 |
| US-11633376-B2 | Method for treating metastatic prostate cancer | BPHL, KLK3, ACP3 | POLB 1583/4885NPSR1 1562/4885L3MBTL1 2958/4885 |
| US-20250127749-A1 | METHOD FOR TREATING METASTATIC PROSTATE CANCER | BPHL, KLK3, ACP3 | POLB 1583/4885NPSR1 1562/4885L3MBTL1 2958/4885 |
| US-20210228528-A1 | METHOD FOR TREATING METASTATIC PROSTATE CANCER | BPHL, KLK3, ACP3 | POLB 1583/4885NPSR1 1562/4885L3MBTL1 2958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.